免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征 Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis. PubMed 2026/09/19 发表Hum PatholQ2 · IF 3(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤
下一代基于抗体的癌症治疗:抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用 Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors PubMed 2026/09/09 发表J Hematol OncolQ1 · IF 47.8(JCR 2025) 靶点:CD19靶点:CD20靶点:BCMA技术:CAR-T技术:双特异性抗体急性淋巴细胞白血病多发性骨髓瘤B细胞淋巴瘤
AML/MDS 细胞治疗的最新进展 Recent advances in cell therapy for AML/MDS. PubMed 2026/09/04 发表Int J HematolQ3 · IF 1.9(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:CAR-NK技术:NK 细胞骨髓增生异常综合征急性髓系白血病多发性骨髓瘤
多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性:EADV 工作组立场文件与实践建议 Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations. PubMed 2026/08/19 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤淋巴瘤白血病
复发/难治性多发性骨髓瘤中双特异性抗体与 CAR-T 细胞治疗的真实世界分析:全球 TriNetX 发现与当代验证队列 Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemp PubMed 2026/07/28 发表Leuk LymphomaQ3 · IF 2.1(JCR 2025) 靶点:BCMA技术:CAR-T技术:双特异性抗体多发性骨髓瘤淋巴瘤白血病
我如何治疗浆细胞白血病 How I treat plasma cell leukemia. PubMed 2026/07/23 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
CD19 与 BCMA 靶向 CAR-T 细胞治疗中输注前宿主骨髓易感性:克隆性造血、血液毒性与治疗相关髓系肿瘤 Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloi PubMed 2026/07/18 发表Cancer Manag ResQ3 · IF 2.6(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T多发性骨髓瘤淋巴瘤地区:中国
智胜抗原逃逸:用于血液系统恶性肿瘤持久缓解的下一代 CAR-T 细胞工程策略 Outsmarting Antigen Escape: Next-Generation CAR T Cell Engineering Strategies for Durable Remissions in Hematologic Malignancies. PubMed 2026/07/01 发表Eur J HaematolQ2 · IF 2.6(JCR 2025) 靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤急性淋巴细胞白血病多发性骨髓瘤地区:其他地区:亚太其他
低频 PPM1D 基因突变对多发性骨髓瘤 BCMA 靶向 CAR-T 细胞治疗反应的影响 Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. PubMed 2026/06/23 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:BCMA技术:CAR-T多发性骨髓瘤淋巴瘤地区:欧洲
CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除:一项系统综述 Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review. PubMed 2026/06/22 发表Bone Marrow TransplantQ1 · IF 5.1(JCR 2025) 靶点:CD19靶点:CD30靶点:BCMA技术:CAR-T技术:造血干细胞非霍奇金淋巴瘤霍奇金淋巴瘤多发性骨髓瘤